Medigate provides a dedicated medical device security and asset management platform that automatically locates, identifies and manages the security posture of devices connected to hospital networks. The product also supplies device data to power clinical engineering and operational analytics for healthcare organizations. The company plans to use the new funding to execute its vision of becoming healthcare’s security and clinical analytics company and to expand its global footprint. Medigate says its solution helps drive operational efficiencies, reduce CapEx and OpEx, and improve patient experience while reinforcing security from core to edge. The company has received industry recognition including a SINET 16 Innovator Award, placement in Forrester’s New Wave report, inclusion on Forbes’ “Top 20 IoT Startups to Watch,” and Frost & Sullivan’s Enabling Technology Leadership Award. Financially, Medigate completed a $30M Series B and reports total funding of $50M, including a Series A in 2019. Medigate provides a dedicated medical device security and asset management platform that identifies, fingerprints and tags individual medical devices beyond their IP addresses. The platform gives visibility into device types, vendors, protocols and operating systems, applies smart detection through medical context and clinical workflows, and enables informed prevention using domain-specific knowledge. The company positions itself as the industry’s first and leading solution to help providers deliver secure, connected care. Medigate reports traction with a portfolio of strategic customers, including many top hospitals and healthcare systems in the U.S. It closed a $15M Series A and plans to use the funds to accelerate growth and triple headcount across R&D, sales, marketing and customer success over the next 18 months. The company and investors cite increasing regulatory scrutiny of medical device security and growth in connected devices as key market drivers. Medigate builds a dedicated platform to secure networked medical devices by discovering devices, fully identifying their types and personalities, and analyzing specialized protocols and behaviors. The solution fuses medical workflow knowledge with device identity and protocol analysis to detect anomalies and block network attacks and data exfiltration. Medigate targets devices that cannot be patched or managed with traditional endpoint security, focusing on network-level protections that understand medical-device protocols. The platform is currently in limited availability to qualified customers, with general availability planned for mid-2018. Financially, the company announced $5.35M in seed funding to support product development and go-to-market expansion. Investors in the announced round include YL Ventures and Blumberg Capital.

Total raised

$50M

Funding rounds

3

Latest round

Series B

Latest activity

Sep 2020